Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Elagolix Sodium

FDA-approved product (tablet, oral), marketed as Orilissa.

Registered studies
24
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Elagolix Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Endometriosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-gonadotropin-releasing hormones
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Elagolix Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Elagolix Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

    NCT01817530 · start 2013-04-08

    Registered record
    Registry ID
    NCT01817530
    Conditions
    Heavy Uterine Bleeding; Uterine Fibroids
    Interventions
    Elagolix placebo; Elagolix; 0.5 mg estradiol / 0.1 mg norethindrone acetate; 1 mg estradiol / 0.5 mg norethindrone acetate; E2/NETA placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-04-08
    Completion
    2015-12
    Enrolment
    571

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeavy Uterine Bleeding; Uterine Fibroids
    InterventionElagolix placebo; Elagolix; 0.5 mg estradiol / 0.1 mg norethindrone acetate; 1 mg estradiol / 0.5 mg norethindrone acetate +1 more
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain

    NCT01760954 · start 2012-12-28

    Registered record
    Registry ID
    NCT01760954
    Conditions
    Endometriosis
    Interventions
    Elagolix
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-12-28
    Completion
    2016-04-15
    Enrolment
    506

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionElagolix
    PhasePhase 3
    Registry statusCompleted

  • A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain

    NCT01620528 · start 2012-05-22

    Registered record
    Registry ID
    NCT01620528
    Conditions
    Endometriosis
    Interventions
    elagolix; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-05-22
    Completion
    2015-09-28
    Enrolment
    872

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    Interventionelagolix; placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

    NCT01441635 · start 2011-09-08

    Registered record
    Registry ID
    NCT01441635
    Conditions
    Heavy Uterine Bleeding; Uterine Fibroids
    Interventions
    Elagolix; Placebo; Estradiol/Norethindrone acetate (E2/NETA); Estradiol; Progesterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-09-08
    Completion
    2014-05-17
    Enrolment
    271

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeavy Uterine Bleeding; Uterine Fibroids
    InterventionElagolix; Placebo; Estradiol/Norethindrone acetate (E2/NETA); Estradiol +1 more
    PhasePhase 2
    Registry statusCompleted

  • An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females

    NCT01403038 · start 2011-06

    Registered record
    Registry ID
    NCT01403038
    Conditions
    Folliculogenesis
    Interventions
    Elagolix; Elagolix; Elagolix; Elagolix; Elagolix; Elagolix; elagolix
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-06
    Completion
    2012-11
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFolliculogenesis
    InterventionElagolix; Elagolix; Elagolix; Elagolix +3 more
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety Study of Elagolix in Women With Endometriosis

    NCT00973973 · start 2009-10-12

    Registered record
    Registry ID
    NCT00973973
    Conditions
    Endometriosis, Pain
    Interventions
    Placebo; Elagolix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-10-12
    Completion
    2010-09-22
    Enrolment
    137

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis, Pain
    InterventionPlacebo; Elagolix
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis

    NCT00797225 · start 2008-11-26

    Registered record
    Registry ID
    NCT00797225
    Conditions
    Endometriosis
    Interventions
    Leuprorelin Acetate Depot; Elagolix; Placebo to Elagolix; Placebo to Leuprorelin Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-11-26
    Completion
    2010-02-24
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionLeuprorelin Acetate Depot; Elagolix; Placebo to Elagolix; Placebo to Leuprorelin Acetate
    PhasePhase 2
    Registry statusCompleted

  • An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis

    NCT00619866 · start 2008-02-19

    Registered record
    Registry ID
    NCT00619866
    Conditions
    Endometriosis, Pain
    Interventions
    Elagolix; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02-19
    Completion
    2009-08-28
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis, Pain
    InterventionElagolix; placebo
    PhasePhase 2
    Registry statusCompleted

  • Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis

    NCT00437658 · start 2006-12-11

    Registered record
    Registry ID
    NCT00437658
    Conditions
    Endometriosis
    Interventions
    Elagolix; Subcutaneous depot medroxyprogesterone acetate (DMPA-SC); Placebo to Elagolix; Placebo to DMPA-SC
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-12-11
    Completion
    2008-11-24
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionElagolix; Subcutaneous depot medroxyprogesterone acetate (DMPA-SC); Placebo to Elagolix; Placebo to DMPA-SC
    PhasePhase 2
    Registry statusCompleted